Clinical therapy for renal diseases generally includes angiotensin-converting enzyme inhibitor (ACEI) and Ang II receptor blockers (ARBs) to decrease ACE/Ang II activation and ameliorate disease development. The gene discussed is AGT; the disease is kidney disorder.